Himalaya Nutravedics IPO
Pharmaceuticals • ₹26.5 Cr
High risk because:
- 5 material risk factors disclosed in DRHP
- High customer concentration flagged in the DRHP
- SME listing with thinner post-listing liquidity
IPOFins risk score from DRHP risk factors, subscription demand & issue structure
Price Band
₹106
Lot Size
1200 shares
Issue Size
₹26.5 Cr
Open
22 Sept 2026
Close
24 Sept 2026
Subscription
2.21×
IPO Schedule
| Issue Open Date | 22 Sept 2026 |
| Issue Close Date | 24 Sept 2026 |
| Allotment Date | 25 Sept 2026 |
| Listing Date | 28 Sept 2026 |
About Himalaya Nutravedics
Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. Its product portfolio includes classical Ayurvedic formulations based on recognised Ayurvedic texts, proprietary Ayurvedic formulations and nutraceutical supplements. The products are available in dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. Its nutraceutical products include formulations using vitamins, minerals, herbal extracts, amino acids and other permitted ingredients. The company operates through both its own-brand and third-party manufacturing businesses. It commenced manufacturing operations in September 2022 from its facility in Cherlapally, Hyderabad, Telangana. The company has a stockist-driven distribution network across multiple states in India and an on-ground sales and marketing team of approximately 56 personnel, including regional managers and medical representatives. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Funding capital expenditure requirements — Rs 13.75 crore Investment in branding, digital marketing, and sales expansion — Rs 7.50 crore General corporate purposes.
Company Details
Founders / Promoters
Mr Rohit Asawa
Founded
2022
Registrar
KFin Technologies Ltd
Documents
DRHP / RHP Document (PDF)
View official prospectus →
Investment Analysis
Himalaya Nutravedics — IPOFins Verdict
QuantitativeDriven by QIB demand at 1.0x and elevated disclosed risk (8/10). SME listings are also thinner and more volatile after listing. The signals look weak — weigh the risks carefully. This is a quantitative flag, not a recommendation.
- The company claims to operate an integrated manufacturing facility capable of producing medicated oils, soft gelatin capsules, hard gelatin capsules, tablets and liquid orals. This allows it to manufa
- Since commencing manufacturing operations in September 2022, the company has established a presence across multiple states in India. It has built a stockist-driven distribution network supported by an
- The company offers classical Ayurvedic formulations, proprietary Ayurvedic formulations, and nutraceutical supplements across areas such as gut health, cardiac and metabolic wellness, diabetes managem
- The company operates through both its own-brand business and third-party manufacturing operations. This model allows it to manufacture and market its own formulations while also undertaking contract m
- The company claims that its products have received repeat prescriptions and re-orders from healthcare practitioners while relying on scientific detailing, continuing medical education programmes, medi
Score breakdown — what drove this verdict
High risk from DRHP → score -1.2
Institutional subscription → score 0
SME IPOs have lower liquidity after listing → score −0.5
Base score: 5.0 · Final score = base + all factor adjustments, capped 1–10. Full methodology →
IPOFins Score is a quantitative signal from subscription demand, disclosed risk, and listing data — not investment advice. Not SEBI-registered.
Want to buy this stock?
Trade Himalaya Nutravedics on the secondary market
FAQ
What is the price band of Himalaya Nutravedics IPO?
The price band is ₹106 per share with a lot size of 1200 shares. Minimum investment: ₹1,27,200.
What does Himalaya Nutravedics do?
Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. Its product portfolio includes classical Ayurvedic formulations based on recognised Ayurvedic texts, proprietary Ayurvedic formulations and nutraceutical supplements. The products are available in dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. Its nutraceutical products include formulations using vitamins, minerals, herbal extracts, amino acids and other permitted ingredients. The company operates through both its own-brand and third-party manufacturing businesses. It commenced manufacturing operations in September 2022 from its facility in Cherlapally, Hyderabad, Telangana. The company has a stockist-driven distribution network across multiple states in India and an on-ground sales and marketing team of approximately 56 personnel, including regional managers and medical representatives. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Funding capital expenditure requirements — Rs 13.75 crore Investment in branding, digital marketing, and sales expansion — Rs 7.50 crore General corporate purposes.
Should I apply for Himalaya Nutravedics IPO?
Himalaya Nutravedics is drawing muted interest at 2.2x overall subscription (QIB 1.0x, retail 2.5x). IPOFins Score 3/10: Driven by QIB demand at 1.0x and elevated disclosed risk (8/10). SME listings are also thinner and more volatile after listing. The signals look weak — weigh the risks carefully. This is a quantitative flag, not a recommendation.
Who founded Himalaya Nutravedics?
Himalaya Nutravedics was founded by Mr Rohit Asawa in 2022.